Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-023460
Filing Date
2025-05-08
Accepted
2025-05-08 07:29:11
Documents
95
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20250331.htm   iXBRL 10-Q 1926047
2 EX-31.1 exhibit311-q120251.htm EX-31.1 10971
3 EX-31.2 exhibit312-q120251.htm EX-31.2 11031
4 EX-32.1 exhibit321-q120251.htm EX-32.1 7527
10 GRAPHIC akba-20250331_g1.gif GRAPHIC 3995
  Complete submission text file 0001628280-25-023460.txt   9500722

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20250331.xsd EX-101.SCH 83707
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20250331_cal.xml EX-101.CAL 81914
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20250331_def.xml EX-101.DEF 371698
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20250331_lab.xml EX-101.LAB 852674
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20250331_pre.xml EX-101.PRE 622933
98 EXTRACTED XBRL INSTANCE DOCUMENT akba-20250331_htm.xml XML 1125064
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 25923877
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)